Core Viewpoint - The U.S. will impose a 100% tariff on patented and branded drugs starting October 1, which may impact pharmaceutical companies' operations and supply chains in the U.S. market [1] Company Response - Yifan Pharmaceutical has been monitoring U.S. tariff policies and is optimizing the supply chain and cost strategies for its innovative drug F-627 [1] - The company plans to shift the production and shipping of F-627 to the U.S. to mitigate the impact of tariffs, with the potential for local dispatch as early as next year [1] - Yifan Pharmaceutical asserts that the tariff policy will not have a significant adverse effect on the sales of F-627 in the U.S. market [1]

证券日报网讯亿帆医药（002019）9月24日在互动平台回答投资者提问时表示，截至2025年9月19日公司 股东人数为46838户。 ...

Core Viewpoint - The company is focusing on developing synthetic biological products and has made significant investments in its production capabilities, indicating a strategic shift towards in-house manufacturing and innovation [2]. Group 1: Investment and Production - The company has invested 1 billion yuan in building a new factory in Qidong City, which suggests a potential decision to move away from collaboration with Xinfu [2]. - The company aims to provide natural, green, and sustainable innovative products across various markets, including healthcare, human and animal nutrition, and pharmaceuticals [2]. Group 2: Collaboration and Future Plans - There are questions regarding the future of existing collaborations on products such as Ectoin, Farnesol, and Fucoidan, particularly whether these partnerships will end after their current terms [2].

每经AI快讯，有投资者在投资者互动平台提问：三季报预计几号披露，请提前做好海外公司的财务数 据采集，不要拖沓。 亿帆医药（002019.SZ）9月19日在投资者互动平台表示，（1）深交所预约三季报工作尚未开始；（2） 预计将于10月31日披露三季报，具体时间将以公司在交易所预约的披露时间为准。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019.SZ) has successfully launched its product Yilishu in the United States [1] Group 2 - The company has announced this achievement on its investor interaction platform [1]

Company Overview - Yifan Pharmaceutical's stock price increased by 2.14% on September 18, reaching 14.81 CNY per share, with a trading volume of 176 million CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 18.015 billion CNY [1] - The company was established on November 10, 2000, and went public on July 13, 2004. It is located in Lin'an District, Hangzhou, Zhejiang Province [1] - Yifan Pharmaceutical's main business includes the production and sale of active pharmaceutical ingredients and high polymer materials, with revenue composition as follows: proprietary pharmaceutical products (including imports) 75.52%, vitamins 11.47%, other pharmaceutical products 9.52%, high polymer materials 3.00%, and pharmaceutical services 0.49% [1] Financial Performance - For the first half of 2025, Yifan Pharmaceutical achieved operating revenue of 2.635 billion CNY, a year-on-year increase of 0.11%, and a net profit attributable to shareholders of 304 million CNY, representing a year-on-year growth of 19.91% [2] - The company has distributed a total of 1.328 billion CNY in dividends since its A-share listing, with 243 million CNY distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders of Yifan Pharmaceutical reached 42,900, an increase of 3.38% from the previous period, with an average of 19,634 circulating shares per person, a decrease of 3.27% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 25.5819 million shares, an increase of 2.4783 million shares from the previous period [3]

证券日报网讯 9月16日晚间，亿帆医药发布公告称，公司全资子公司合肥亿帆生物制药有限公司于2025 年9月15日收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。 （文章来源：证券日报） ...

格隆汇9月16日丨亿帆医药(002019.SZ)公布，公司全资子公司合肥亿帆生物制药有限公司于2025年9月 15日收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑 为抗感染药物。适用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 ...

亿帆医药9月16日晚间公告，公司全资子公司合肥亿帆生物制药有限公司获得国家药品监督管理局核准 签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑为抗感染药物，适用于治疗成人患 者下列感染：侵袭性曲霉病、侵袭性毛霉病。截至本报告披露日，除本公司外，中国境内注射用硫酸艾 沙康唑有9家企业获批上市，另有多家企业处于仿制药报产审评中。截至本报告披露日，公司对注射用 硫酸艾沙康唑的研发投入约789.72万元。 ...

亿帆医药（002019）(002019.SZ)公告，公司全资子公司合肥亿帆生物制药有限公司于2025年9月15日收 到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑为抗感 染药物，适用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 ...